You are here

Vascular & Endovascular

 

Bikram yoga—a form of “hot yoga” in which poses are practiced in a room heated to upwards of 104 degrees Fahrenheit (40 degrees Celsius)—has cardiovascular benefits, but no more than yoga practiced at room-temperature, teams at the University of Texas at Austin and Texas State University have found.

Individuals with chronic kidney disease (CKD) are at increased risk of stroke and more likely to die as a result of stroke than the general population, and those with end-stage renal disease (ESRD) are especially at risk, according to a study published in PLOS One.

General anesthesia during endovascular therapy (EVT) for acute ischemic stroke was tied to better outcomes than conscious sedation in a randomized single-center study, contrasting with findings from previous observational trials.

High-intensity statin therapy for peripheral artery disease (PAD) patients reduces the risk of lower-extremity amputations by one-third and the risk of mortality by 26 percent, a new study found. However, the lipid-lowering drugs remain underutilized in the PAD population despite their guideline-recommended use.

Stroke may be linked to an increased risk of dementia, but cognitive decline isn’t an inevitable consequence of the event, researchers reported in the Journal of the American Heart Association this week.

 

Recent Headlines

Bard Q4 earnings slip, FY09 up due to higher sales C. R. Bard has reported an increase in net income for the fiscal year 2009, despite an earnings dip in the 2009 fourth quarter that ended Dec. 31.
FDA, ev3 recall Trailblazer catheter due risk to patients The FDA and ev3 Endovascular have issued a Class I recall of the Trailblazer support catheter, because the device may crack near the radiopaque marker band, resulting in serious patient injury, including insufficient oxygen supply to the tissues, damage to blood vessels, heart attack, limb amputation, unplanned surgery and/or death.
Atherectomy: The Little Devices that Could As the incidence of peripheral arterial disease (PAD) rises, endovascular interventions continue to gain wider acceptance. Yet, questions remain regarding which patients benefit most from atherectomy devices.
The Back Page: Transradial Myths Dispelled, Hurdles ConqueredAdopt Now Interventionalists Perspective Dr. Hall Administrators Perspective Mr. Stewart
Circulation: Cardiac arrest survival at home or work unchanged in 30 years
The chance of surviving an out-of-hospital cardiac arrest at work or in the home has not improved since the 1950s, according to a report published online Nov. 10 in Circulation: Cardiovascular Quality and Outcomes.
NEJM: New anticoagulant as good as warfarin, without the lab monitoring For the treatment of acute venous thromboembolism (VTE), a fixed dose of the new anticoagulant dabigatran (Pradaxa; Boehringer Ingelheim) is as effective as warfarin, has a safety profile that is similar to that of warfarin and does not require laboratory monitoring, based on the findings of the RE-COVER trial published online Dec. 6 in the New England Journal of Medicine.
Cardiovascular Systems losses narrow in 2010 Q1, due to increased sales Cardiovascular Systems, a developer of interventional treatment systems for vascular disease, has reported financial results for its fiscal first quarter of 2010, which ended Sept. 30.
Cook unveils five PAD products Cook Medical is introducing five new products, which seek to treat peripheral arterial disease (PAD) and other diseases of the circulatory system.
Interventionalists become aggressive treating DVT
In the United States, 200,000 people die from a pulmonary embolism (PE) each year. Most PEs originate from deep vein thrombosis (DVT). Interventionalists are using many therapies and devices to help reduce the harm caused by DVT.

Pharmacomechanical thrombectomy is one such approach that involves using a combination of a lysing agent and a mechanical action to dissolve and collect the thrombus.
Covidien enters DVT therapy market Covidien, known for its peripheral guidewires, entered the pharmacomechanical thrombectomy market about six months ago by acquiring Bacchus Vascular, makers of the Trellis-8 Peripheral Infusion System.

Pages